259 related articles for article (PubMed ID: 22435504)
21. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.
Kane S; Huo D; Magnanti K
Clin Gastroenterol Hepatol; 2003 May; 1(3):170-3. PubMed ID: 15017487
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Cohen RD; Woseth DM; Thisted RA; Hanauer SB
Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
[TBL] [Abstract][Full Text] [Related]
23. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
Ford AC; Achkar JP; Khan KJ; Kane SV; Talley NJ; Marshall JK; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):601-16. PubMed ID: 21407188
[TBL] [Abstract][Full Text] [Related]
25. Extended-release mesalamine granules for ulcerative colitis.
Love BL; Miller AD
Ann Pharmacother; 2012 Nov; 46(11):1529-36. PubMed ID: 23115226
[TBL] [Abstract][Full Text] [Related]
26. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.
Hawthorne AB; Stenson R; Gillespie D; Swarbrick ET; Dhar A; Kapur KC; Hood K; Probert CS
Inflamm Bowel Dis; 2012 Oct; 18(10):1885-93. PubMed ID: 22081522
[TBL] [Abstract][Full Text] [Related]
27. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
28. Does treatment schedule matter? Once daily versus divided doses of 5-ASAs.
Kane S
Dig Dis; 2010; 28(3):478-82. PubMed ID: 20926875
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
30. Once-daily mesalamine granules for ulcerative colitis.
Lawlor G; Ahmed A; Moss AC
Expert Rev Clin Immunol; 2010 Jul; 6(4):521-6. PubMed ID: 20594123
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
[TBL] [Abstract][Full Text] [Related]
33. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis.
Ford AC; Khan KJ; Achkar JP; Moayyedi P
Am J Gastroenterol; 2012 Feb; 107(2):167-76; author reply 177. PubMed ID: 22108446
[TBL] [Abstract][Full Text] [Related]
35. Curcumin for maintenance of remission in ulcerative colitis.
Kumar S; Ahuja V; Sankar MJ; Kumar A; Moss AC
Cochrane Database Syst Rev; 2012 Oct; 10():CD008424. PubMed ID: 23076948
[TBL] [Abstract][Full Text] [Related]
36. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
37. Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Horst SN; Kane S
Expert Opin Pharmacother; 2012 Oct; 13(15):2225-32. PubMed ID: 22970981
[TBL] [Abstract][Full Text] [Related]
38. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
[TBL] [Abstract][Full Text] [Related]
39. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Zakko SF; Gordon GL; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
Postgrad Med; 2016; 128(3):273-81. PubMed ID: 26861051
[TBL] [Abstract][Full Text] [Related]
40. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]